| Identification | Back Directory | [Name]
4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole | [CAS]
374886-51-8 | [Synonyms]
ASP 2535
4-[3-(1-Methylethyl)-5-(6-phenyl-3-pyridinyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole | [Molecular Formula]
C22H18N6O | [MOL File]
374886-51-8.mol | [Molecular Weight]
382.42 |
| Chemical Properties | Back Directory | [Boiling point ]
607.3±65.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
1.55±0.12(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
ASP 2535 is a a novel and centrally active GlyT1 inhibitor, which can improve cognitive impairment in animal models of schizophrenia and Alzheimer''s disease. | [in vivo]
ASP2535 (0.3-3 mg/kg; p.o) attenuates working memory deficit in MK-801-treated mice and visual learning deficit in neonatally phencyclidine (PCP)-treated mice[1].
ASP2535 (1-3 mg/kg, p.o.) also improves the PCP-induced deficit in prepulse inhibition in rats[1].
| Animal Model: | 5-week-old male ddY mice[1] | | Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg | | Administration: | Oral administration | | Result: | Significantly attenuated the MK-801-induced decrease in alternation rate. |
| [storage]
Store at -20°C |
|
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|